Health Care & Life Sciences » Biotechnology | Theratechnologies Inc.

Theratechnologies Inc. | Cash Flow

Fiscal year is December-November. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
4,055.00
10,541.00
1,571.00
410.00
18,450.00
6,013
Depreciation, Depletion & Amortization
104.00
1,142.00
1,917.00
2,108.00
1,992.00
5,507
Other Funds
5,961.00
265.00
2,472.00
3,383.00
7,924.00
1,808
Funds from Operations
9,912.00
9,134.00
5,960.00
5,901.00
8,534.00
360
Changes in Working Capital
2,168.00
1,095.00
1,126.00
3,210.00
10,989.00
84
Net Operating Cash Flow
7,744.00
8,039.00
7,086.00
2,691.00
2,455.00
444
Capital Expenditures
-
829.00
-
1,599.00
95.00
Sale of Fixed Assets & Businesses
60.00
3.00
68.00
-
-
Purchase/Sale of Investments
7,139.00
8,569.00
2,333.00
10,979.00
20,607.00
Net Investing Cash Flow
7,199.00
7,766.00
2,534.00
12,574.00
20,761.00
Issuance/Reduction of Debt, Net
-
-
5,398.00
5,196.00
5,390.00
Net Financing Cash Flow
-
-
4,525.00
4,855.00
17,694.00
Net Change in Cash
545.00
273.00
14,656.00
14,291.00
701.00
Free Cash Flow
7,744.00
8,040.00
7,086.00
2,660.00
2,413.00
Other Sources
-
23.00
133.00
4.00
-
Change in Capital Stock
-
-
9,923.00
341.00
23,084.00
Exchange Rate Effect
-
-
511.00
447.00
1,313.00
Other Uses
-
-
-
-
59.00

About Theratechnologies

View Profile
Address
2015 Peel Street
Montréal Québec H3A 1T8
Canada
Employees -
Website http://www.theratech.com
Updated 07/08/2019
Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). It offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montreal, Canada.